DiagnoCure buys Catalyst diagnostics technology in $3m cash-and-stock deal:
This article was originally published in Clinica
Executive Summary
Diagnostics and lab services specialist DiagnoCure has acquired Catalyst Oncology (Worcester, Massachusetts), gaining access to the latter's prognostic tests for cancer, including breast and colon. The deal sees Quebec City, Canada-based DiagnoCure pay a $3m mix of cash and shares upfront, and potential milestone payments at a later date. Although Catalyst's tests have been validated in clinical studies involving five tumour types, DiagnoCure intends to develop the technology by conducting additional clinical studies.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.